Clinical Trials Logo

Coronary Stent Implantation clinical trials

View clinical trials related to Coronary Stent Implantation.

Filter by:
  • None
  • Page 1

NCT ID: NCT06300268 Not yet recruiting - Clinical trials for Coronary Artery Disease

Advapro Coronary Stent System in Coronary Artery Diseased Patients.

RESTORE
Start date: June 2024
Phase: N/A
Study type: Interventional

A Prospective, Multicentre, Pilot Study to Evaluate the Safety and Performance of the AdvaPro Sirolimus Eluting Coronary Stent System in Coronary Artery Stenosis in Indian and European Population. To evaluate the performance of AdvaPro Sirolimus Eluting Stent follow up indicated by MACE at 9 months. Of the 120, 40 patients will be assigned to European population and 80 patients will be assigned to Indian population. QCA is applicable for only in sub-strategy participants at baseline and 9 month follow-up visit. A QCA Analysis will be performed on minimum 48 patients in Indian population only. Interval(Days) for patients visit at Day 0, Day 30±6, Day 180±8, Day 270±10 and Day 360±14.

NCT ID: NCT04255602 Recruiting - Clinical trials for Acute Coronary Syndrome

A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients

TIGER
Start date: February 19, 2020
Phase: Phase 4
Study type: Interventional

This study is to evaluate the safety and efficacy of 60mg ticagrelor plus 100mg Aspirin to prevent major adverse cardiovascular and cerebrovascular events in one years after drug-eluting stents implantation for Chinese ACS patients compared with 90mg ticagrelor plus 100mg Aspirin

NCT ID: NCT03620760 Recruiting - Clinical trials for Unstable Angina Pectoris

Efficacy and Safety of Low Dose Ticagrelor in Patients With Unstable Angina Pectoris After Coronary Stent Implantation

Start date: August 7, 2018
Phase: Phase 4
Study type: Interventional

The study is to evaluate efficacy and safety of low dose of ticagrelor therapy for Chinese unstable angina patients treated with non-urgent coronary stent implantation, to examine whether lower dose ticagrelor (45 mg twice-daily) is not inferior to standard dose (90 mg twice-daily) for the prevention of major adverse cardiovascular and cerebrovascular events, as well as will reduce the incidence of bleeding during long-term treatment.

NCT ID: NCT01515345 Completed - Clinical trials for Coronary Stent Implantation

Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry

IDEAL-PCI
Start date: July 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of a routine individualized antiplatelet therapy after coronary stent implantation by evaluating "on-treatment" platelet reactivity with Multiple Electrode Aggregometry (MEA, Multiplate® Analyzer).